Overview: SLU-PP-332 is a preclinical small molecule, not a peptide or approved exercise pill. Review the mouse studies, 2026 research and missing human evidence.
On this page
SLU-PP-332 is an experimental small molecule studied mainly in mice—not a peptide and not a proven “exercise pill.”
Researchers developed SLU-PP-332 as an agonist of oestrogen-related receptors, transcriptional regulators involved in cellular energy metabolism. Mouse studies report endurance and metabolic effects. No human efficacy trial has established that these findings translate to people.
What SLU-PP-332 is—and is not
| Question | Answer |
|---|---|
| Is it a peptide? | No. It is a synthetic small molecule. |
| What does it target? | Oestrogen-related receptors, especially ERRα-linked transcriptional pathways involved in oxidative metabolism. |
| Where is the efficacy evidence? | Primarily cell and mouse experiments. |
| Has it been proven to mimic exercise in humans? | No human clinical efficacy trial was identified. |
| Is it an approved medicine? | No established therapeutic approval was identified. |
The “exercise mimetic” phrase is a useful research shorthand for activating some molecular programmes associated with endurance training. It does not mean a compound reproduces the cardiovascular, musculoskeletal, neurological and behavioural effects of actual exercise.
What the key studies found
| Year | Model | Main observation | Translation limit |
|---|---|---|---|
| 2023 | Mouse skeletal muscle and exercise testing | ERR activation increased oxidative muscle fibres and endurance-related measures | Animal performance does not predict a safe or useful human dose |
| 2023 | Diet-induced obese mice | Reported increased energy expenditure and improved selected metabolic measures | Mouse obesity models do not establish human fat-loss efficacy |
| 2026 | Chemical optimisation research | Researchers developed related compounds while refining potency and selectivity | Ongoing optimisation signals an early-stage programme, not clinical validation |
| 2026 | Laboratory metabolism assays | Researchers identified candidate metabolites for possible doping-control detection | Analytical work does not establish human efficacy or safety |
Why human translation is uncertain
ERRs influence many tissues and gene networks. A compound that changes energy metabolism may also create unwanted effects that short animal studies cannot reveal. Human development would need a clearly defined formulation, toxicology, pharmacokinetics, dose-ranging, interaction assessment and controlled trials measuring clinically meaningful outcomes.
| Popular claim | What supports it | Current evidence grade |
|---|---|---|
| “Exercise in a pill” | Mouse endurance and muscle-metabolism findings | Preclinical only |
| Fat loss | Metabolic effects in obese mice | Preclinical only |
| Improved human endurance | No published human efficacy trial identified | Unproven |
| Anti-ageing | Emerging aged-mouse research | Speculative for humans |
| Long-term safety | No adequate clinical safety programme | Unknown |
Detection research does not prove widespread use or safety
Analytical scientists have begun studying SLU-PP-332 metabolism and methods that could identify it in biological samples. That work is relevant to emerging doping risks. It should not be misread as proof that the compound is approved, safe, effective or already common in athletes.
Australian context
Calling a product a “research chemical” does not make it a clinically tested supplement or medicine. Australian regulatory treatment depends on the product, claims, ingredients and supply pathway. Consumers should not infer quality, legality or approval from a vendor label.
Questions readers ask
Is SLU-PP-332 a peptide?
No. It is a synthetic small molecule. It is often grouped with peptides by online sellers, but that is chemically inaccurate.
Does it replace exercise?
No. Mouse studies show changes in selected metabolic and endurance measures. A molecule cannot be assumed to reproduce the many established benefits of human exercise.
Has SLU-PP-332 been tested in humans?
We did not identify a published human efficacy trial. The evidence base remains preclinical.
Why are scientists studying it?
It is a tool for understanding how oestrogen-related receptors control oxidative metabolism and whether related compounds could become therapeutic leads.
Does detection research mean it is approved?
No. Analytical detection work addresses identification and metabolism; it does not establish medical approval, benefit or safety.
Primary sources
- Billon et al. — ERR agonism, oxidative muscle fibres and endurance in mice
- Mouse obesity and metabolic study of SLU-PP-332
- 2026 medicinal-chemistry optimisation of ERR agonists
- 2026 in-vitro metabolite analysis for doping-control purposes
- 2026 analytical characterisation of SLU-PP-332 and SLU-PP-915
Scope: Evidence and regulatory information only. This page does not provide dosing, administration, sourcing or personal medical advice. No independent clinician reviewer is attributed to this update.
How to cite this research profile
SLU-PP-332: Mouse Evidence, “Exercise Mimetic” Claims and Human Gaps. Elite Peps Australia. Published 30 June 2026; updated 30 September 2026. https://elitepepsaustralia.com/product/slupp-332/
Verification: Follow the linked primary studies, trial records and regulator documents in the references above. Regulatory status is date-sensitive.